Can drug treatment center real estate outperform other investments?

Investment·Last updated Sep 14, 2026

The available evidence does not support a general claim that drug treatment center real estate outperforms other investments. Interest in the sector is real, but standardized, independently verified return data for this property niche is not available.

Short answer: the claim requires verification

No authoritative benchmark identified for this article isolates drug treatment center real estate as an asset class and compares its realized returns with office, retail, housing, stocks, or bonds. A property may perform well, but that outcome cannot be inferred from its treatment use alone.

Real estate returns and operator returns are different

Revenue, EBITDA, return-on-equity, and internal-rate-of-return figures for a treatment business are not evidence of a landlord's property return. The operating business depends on admissions, staffing, clinical compliance, payer contracts, collections, and licensing. The real estate depends on purchase basis, rent, tenant credit, lease terms, capital work, financing, residual value, and the ability to re-tenant or convert the building.

What the cited market material can and cannot show

Hendon Partners describes buyer interest and transaction drivers in addiction-treatment mergers and acquisitions. That is useful market commentary, but it is not an audited study of property returns. FinModelsLab publishes model-based business-owner estimates and sells financial templates. Those projections are hypothetical, depend on user assumptions, and should not be treated as verified real-estate performance.

Risks that can change the result

• Tenant risk: rent depends on the operator's ability to maintain compliance and cash flow.
• Reimbursement risk: coverage, enrollment, authorization, network status, denials, and collections can change.
• Special-use risk: a failed single-purpose facility can be expensive to re-tenant or convert.
• Approval risk: zoning feasibility does not equal a license, certificate, accreditation, or payer enrollment.
• Capital risk: accessibility, fire, life-safety, building-system, and resident-safety upgrades can alter returns.
• Concentration risk: one property, one operator, or one payer can make cash flow fragile.

How a buyer can test an outperformance thesis

• Define whether the comparison concerns real estate, the operating company, or both.
• Use realized property cash flows rather than a seller's business projections.
• Compare risk-adjusted returns after financing, reserves, downtime, capital work, and exit costs.
• Stress-test reimbursement delays, occupancy declines, license interruption, and tenant failure.
• Compare the treatment-use value with a supported alternate-use valuation.
• Have qualified legal, licensing, tax, clinical, and investment professionals verify assumptions.

Sources reviewed

• Hendon Partners: Addiction Treatment and Substance Abuse M&A in 2026 — third-party advisory commentary.
• FinModelsLab: treatment-center owner estimates — third-party modeled estimates, not verified property returns.
• CMS: opioid treatment program enrollment requirements.
• CMS: opioid treatment program billing and payment.

Last researched: September 14, 2026.